Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHA, Sorrento JV Highlights Korean Immuno-Oncology Appetite

Executive Summary

Sorrento and CHA Biotech’s agreement to form a CAR-NK cell therapy joint venture is very much “on trend”, being the latest in a recent series of immuno-oncology collaborations between Korean and foreign firms and indicating a rapidly growing appetite for assets in the field.

You may also be interested in...



Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

Korean Stem Cell Ventures Pursuing Divergent R&D Strategies

Two South Korean stem cell therapy ventures, Corestem and CHA Biotech, are taking divergent strategies in R&D and commercialization, one pushing ahead with the rapid launch of its first product and the other taking time to optimize its pipeline. During a recent stem cell industry investor relations session in Seoul, the companies unveiled the thinking behind their pipeline progress and business strategies.

Korea Seeks Two-Track Strategy For COVID-19 Drugs, Vaccines

As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.

Topics

Related Companies

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel